NNC0165-1875
A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity
Novo Nordisk · Phase 2 · Completed · Enrollment 120
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Semaglutide 2.4 mg and NNC0165-1875 2.0 mg | Obesity or overweight | 2.4 mg and 2.0 mg | 26 | n/r | n/r |
| Semaglutide 2.4 mg and placebo 2.0 mg(NNC0165-1875 2.0 mg) | Obesity or overweight | 2.4 mg and 2.0 mg and 2.0 mg | 26 | n/r | n/r |
| Semaglutide 2.4 mg and NNC0165-1875 1.0 mg | Obesity or overweight | 2.4 mg and 1.0 mg | 26 | n/r | n/r |
| Semaglutide 2.4 mg and placebo 1.0 mg(NNC0165-1875 1.0 mg) | Obesity or overweight | 2.4 mg and 1.0 mg and 1.0 mg | 26 | n/r | n/r |